Adial Pharmaceuticals, Inc. completed the acquisition of Azora Therapeutics, Inc. as part of a merger agreement, issuing shares of common and preferred stock to Azora's stockholders.

US · 2026-09-16

1. Step 1 · The triggerAdial Pharmaceuticals issues new common and preferred shares to acquire Azora Therapeutics, increasing its outstanding share count and introducing preference claims.
2. Step 2 · Knock-onThe capital structure shift dilutes existing shareholders and may alter Adial's cost of capital and risk profile, affecting its ability to fund operations and honor supplier or partner contracts.
3. Step 3 · Reaches youUS SMEs with exposure to Adial as a customer or partner face changed counterparty risk and may need to review contract terms or renegotiate to protect their position.

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: SEC EDGAR — Current filings

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.